Sanofi SA (SNY) reported positive data from the Phase 2 ElevAATe study of efdoralprin alfa in adult patients with alpha-1 antitrypsin deficiency-related emphysema.
Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic condition characterized by low levels or absence of alpha-1 antitrypsin, a protein that helps protect the lungs from inflammation-related damage.
The study was designed to evaluate efdoralprin alfa against a standard-of-care augmentation therapy in patients with AATD-related emphysema. Patients were randomized in a 2:2:1 ratio to receive efdoralprin alfa every three or four weeks, or plasma-derived augmentation therapy once weekly.
Efdoralprin alfa administered every three weeks achieved mean increases in functional alpha-1 antitrypsin trough levels more than three times greater than plasma-derived augmentation therapy given weekly, meeting the study's primary endpoint.
Further, patients receiving the every-three-week regimen maintained functional alpha-1 antitrypsin levels above the normal threshold of 23.8 µM for 100% of days during the 32-week study, compared with 41% of days for patients receiving standard-of-care therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.